Key stories dominating global financial media overnight include signals from the Federal Reserve on potential rate increases, a major vaccine trial breakthrough for Moderna, a strategic move by the U.S. Treasury to stabilize the bond market, and OpenAI's potential public listing timeline.
The latest Federal Reserve meeting minutes revealed that several officials leaned toward raising interest rates last month, with many policymakers stating that tighter monetary policy would be necessary if inflation fails to subside. However, lingering uncertainties kept Fed officials highly cautious during the July 28-29 session. The Federal Open Market Committee (FOMC) minutes released Wednesday noted that "regarding the outlook for monetary policy, participants reiterated that their interpretation of the latest information would be an important component of policy discussions."
Where the Standoff Stands on Frozen Funds
The governor of Iran's central bank stated that "so far, none of Iran's frozen assets have been returned under the memorandum of understanding signed with the United States." According to the June agreement, $12 billion in frozen Iranian funds were expected to be released, including $6 billion held in Qatar. He expressed hope that the agreement could be revived, adding that the memorandum serves Iran's interests and required significant effort to negotiate, making it a potentially solid foundation for continued dialogue.
OpenAI's CFO Signals Potential 2027 IPO
According to two sources familiar with the matter, OpenAI's Chief Financial Officer Sarah Friar told employees during an all-hands meeting Wednesday that the company is targeting a public listing in 2027, or possibly earlier if business growth continues at its current rapid pace. "An IPO is not the finish line; it's just a milestone, another round of funding," Friar told staff. "We completed our financing in March, which gives us ample room to maneuver." OpenAI confidentially filed IPO documents with the U.S. Securities and Exchange Commission in June, though no specific listing timeline was disclosed at that time.
Marvell Shares Jump on Expanded AI Chip Pact with Google
Marvell Technology shares closed up 9.85% following the disclosure of a securities filing revealing an expanded agreement that allows Google to purchase up to $12.2 billion in shares. The deal, part of the companies' custom chip partnership, permits the tech giant to acquire up to 58,970,907 shares at $206.58 per share. The equity stake is tied to procurement targets through fiscal 2033. Marvell noted in the filing that the expanded agreement covers products tied to the TPU ecosystem, including AI inference accelerators, storage, and network interface controllers.
Moderna Soars as Melanoma Vaccine Trial Meets Key Goals
Moderna and Merck announced Wednesday that their mRNA vaccine combined with immunotherapy drug Keytruda succeeded in a late-stage clinical trial for skin cancer. The company's shares surged 176.97% at the close. While the study remains ongoing, interim results showed the treatment, known as Intismeran, achieved its primary goal of reducing cancer recurrence as well as the secondary goal of preventing the disease from spreading to other parts of the body.
Treasury Doubles Debt Buyback Program to Steady Bond Market
The U.S. Treasury announced Wednesday that it will more than double the size of its government debt buyback program, a move that pushed yields significantly lower amid considerable market pressure. With fixed-income markets under strain and yields climbing to levels not seen in nearly two decades, the announcement targeted the sensitive long-duration segment of the Treasury market. Under the accelerated repurchase plan, the Treasury, led by Secretary Scott Bessent, will focus on the 10-to-20-year and 20-to-30-year segments, which have experienced a lack of buyers since late June.